Eloxx Pharmaceuticals Inc
ELOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$51.79M
Close$
$3.38
76.2% downside
Current Fair Value
76.2% downsideOvervalued by 76.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $51.79 Million |
|---|---|
| Enterprise Value | $-10,174,748.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.34 |
| Beta | -9.95 |
| Outstanding Shares | 6,789,165 |
Return
| Return on Equity | -34.88% |
|---|---|
| Return on Assets | -25.54% |
| Return on Invested Capital | -34.86% |
Valuation & Multiples
| P/E Ratio | -9.91 |
|---|---|
| PEG | -39.13 |
| Price to Sales | - |
| Price to Book Ratio | 2.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.63 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-70.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 57.04%▲ 57.04% |
|---|---|
| Total Invested | $34.70M |
| Investors Holding | 22▲ 22.00% |
ESG Score
No data
About Eloxx Pharmaceuticals Inc
CEO: Robert Ward